Burst Technologies

AmideBio LLC, located in Louisville, CO, is a leading biotechnology company specializing in the development of novel peptides for targeting metabolic diseases. With a focus on drug discovery and custom synthesis, AmideBio offers a wide range of peptide products and services to meet the needs of the pharmaceutical industry. Driven by a commitment to innovation and collaboration, AmideBio is dedicated to providing high-quality peptides that address the growing demand for effective treatments in the field of metabolic disease. With a team of experienced professionals and state-of-the-art facilities, AmideBio is at the forefront of peptide research and development, offering cutting-edge solutions to improve patient outcomes.Generated from the website

Msbiotec is a biotechnology company based in Greenwood Village, CO. Specializing in research and development, the company focuses on creating innovative solutions in the field of biotechnology. With a team of dedicated scientists and experts, Msbiotec is committed to advancing scientific knowledge and pushing the boundaries of biotechnological advancements. The company's work encompasses a wide range of applications, contributing to the growth and evolution of the biotechnology industry. Generated from their business information

ARCA Biopharma is a late-stage biopharmaceutical company based in Westminster, CO, specializing in tailored healthcare and pharmacogenetic precision medicine for cardiovascular disease, particularly atrial fibrillation. They aim to address the unmet medical need for safe and effective drug therapies for patients with atrial fibrillation and heart failure, utilizing their potentially groundbreaking genetically-targeted AF treatment, Gencaro. With a focus on precision medicine, ARCA Biopharma recognizes that individual patients respond differently to their disease and treatment, and they strive to develop personalized medical treatments based on the unique characteristics of each patient. Their research and clinical trials, such as the rNAPc2 AB201 clinical trial, aim to improve the success rate of common drug therapies, which currently only have a success rate of 1/3 to 2/3. As cardiovascular disease remains the leading cause of death in the United States, ARCA Biopharma's innovative approach holds promise in revolutionizing the treatment of atrial fibrillation and improving patient outcomes.Generated from the website